Literature DB >> 20434411

Quantification of CLR1401, a novel alkylphosphocholine anticancer agent, in rat plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometric detection.

Hongliang Jiang1, Michelle J Cannon, Maria Banach, Anatoly N Pinchuk, Giangthy N Ton, Christie Scheuerell, Marc A Longino, Jamey P Weichert, Richard Tollefson, William R Clarke, Qin C Ji, Xiangyu Jiang.   

Abstract

A rapid and specific LC-MS/MS based bioanalytical method was developed and validated for the determination of 18-(p-iodophenyl)octadecyl phosphocholine (CLR1401), a novel phosphocholine drug candidate, in rat plasma. The optimal chromatographic behavior of CLR1401 was achieved on a Kromasil silica column (50 mm x 3 mm, 5 microm) under hydrophilic interaction chromatography. The total LC analysis time per injection was 2.8 min with a flow rate of 1.5 mL/min under gradient elution. Liquid-liquid extraction in a 96-well format using ethyl acetate was developed and applied for method validation and sample analysis. The method validation was conducted over the curve range of 2.00-1000 ng/mL using 0.0500 mL of plasma sample. The intra- and inter-day precision and accuracy of the quality control samples at low, medium, and high concentration levels showed < or = 5.9% relative standard deviation (RSD) and -10.8 to -1.4% relative error (RE). The method was successfully applied to determine the toxicokinetics of CLR1401 in rats from three dose groups of 0.4, 4.0, and 10.0 mg/kg/day via intravenous administration. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20434411     DOI: 10.1016/j.jchromb.2010.04.002

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  4 in total

1.  In Silico Docking of Alkylphosphocholine Analogs to Human Serum Albumin Predicts Partitioning and Pharmacokinetics.

Authors:  Ray R Zhang; Joseph J Grudzinksi; Tej I Mehta; Ronald R Burnette; Reinier Hernandez; Paul A Clark; Jonathan A Lubin; Anatoly N Pinchuk; Justin Jeffrey; Marc Longino; John S Kuo; Jamey P Weichert
Journal:  Mol Pharm       Date:  2019-07-08       Impact factor: 4.939

2.  Targeted Molecular Radiotherapy of Pediatric Solid Tumors Using a Radioiodinated Alkyl-Phospholipid Ether Analog.

Authors:  Dana C Baiu; Ian R Marsh; Alexander E Boruch; Ankita Shahi; Saswati Bhattacharya; Justin J Jeffery; Qianqian Zhao; Lance T Hall; Jamey P Weichert; Bryan P Bednarz; Mario Otto
Journal:  J Nucl Med       Date:  2017-07-26       Impact factor: 10.057

3.  A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety.

Authors:  Joseph J Grudzinski; Benjamin Titz; Kevin Kozak; William Clarke; Ernest Allen; LisaAnn Trembath; Michael Stabin; John Marshall; Steve Y Cho; Terence Z Wong; Joanne Mortimer; Jamey P Weichert
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

4.  The LC-MS/MS-Based Measurement of Isopimaric Acid in Rat Plasma and Application of Pharmacokinetics.

Authors:  Doudou Huang; Jiaxi Cheng; Junqin Mao; Senlin Ma; Zenan Du; Wansheng Chen; Feng Zhang; Lianna Sun
Journal:  Biomed Res Int       Date:  2021-10-15       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.